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ABSTRACT
Background Corticobasal degeneration (CBD) is a
complex neurodegenerative disorder. Accurate diagnosis
is increasingly important, with the advent of clinical trials
of drugs aimed at modifying the underlying tau
pathology. CBD often presents with a ‘corticobasal
syndrome’ including impairments of movement and
cognition. However, patients with similar corticobasal
syndromes can have neurodegenerative pathologies that
are not CBD. In addition, patients with CBD may present
with aphasia or behavioural change. The clinical diversity
of CBD and mimicry by non-CBD pathologies hinders
accurate diagnosis.
Methods We applied the new consensus criteria of
Armstrong and colleagues et al1 to a cohort of patients
with detailed longitudinal clinical evaluation and
neuropathology.
Results In patients with pathologically conﬁrmed CBD,
accuracy of diagnosis was similar under the new and
previous criteria: 9/19 (47%) met criteria for probable
CBD at presentation, 13/19 (68%) at last clinical
assessment. Patients with a corticobasal syndrome but
without CBD pathology all (14/14) met the new
diagnostic criteria of probable or possible CBD,
demonstrating that the new criteria lacks the necessary
speciﬁcity for an accurate ante mortem clinical diagnosis
of CBD. None of the clinical features used in the new
criteria were more common in the patients with CBD
pathology (n=19) than without (n=14).
Conclusions The Armstrong criteria usefully broadens
the recognised clinical phenotype of CBD but does not
sufﬁciently improve the speciﬁcity of diagnosis to
increase the power of clinical trials or targeted
applications of tau-based disease-modifying therapies.
Further work is required to show whether biomarkers
could be more effective than clinical signs in the
diagnosis of CBD.
INTRODUCTION
Corticobasal degeneration (CBD) is a challenging
disease with a complex pattern of neurological
impairments and limited diagnostic accuracy, even
in specialist clinics.1–5 For patients, the outlook is
often bleak, with accumulating disability and death,
and few treatment options—none of which has
been shown to alter the underlying disease course.
The importance of CBD lies not only in its rela-
tively young onset, high morbidity and poor prog-
nosis: the pathology also has much in common
with other primary tauopathies, including progres-
sive supranuclear palsy (PSP) and frontotemporal
lobar degeneration associated with tau pathology
(FTLD-tau). This increases the potential impact of
novel therapies, but the development of new
disease-modifying treatments requires accurate
diagnosis. A major limitation has been the similar-
ity of clinical phenotypes between CBD and ‘CBD
mimics’ caused by other pathology such as
Alzheimer’s disease (AD).
Unfortunately, the published literature has been
inconsistent in terminology related to CBD. In this
article, we use ‘CBD’ to refer only to cases with a
neuropathologically conﬁrmed tau pathology
affecting glia and neurons in a characteristic distri-
bution.2 We use ‘CBD mimic’ to refer to cases of
clinically-suspected CBD where the postmortem
pathology was not CBD. Clinical diagnostic criteria
for CBD (‘clinical CBD’) identify a phenotype, or
syndrome, associated with CBD that we call a corti-
cobasal syndrome (CBS). CBS includes a mixed
movement disorder (eg, levodopa-unresponsive
rigidity associated with apraxia, dystonia, myoclo-
nus and alien limb) and impaired cognition.
In early reports, CBD was principally thought of
as a movement disorder that did not compromise
higher order cognition.6 7 More recently, a broader
clinical phenotype of CBD pathology has emerged
in several sets of consensus criteria for CBD and
CBS1 5 7 Cognitive features were ﬁrst included by
Boeve et al7 with speech apraxia and frontal execu-
tive dysfunction. Bak and Hodges later expanded
the cognitive proﬁle of CBS (including CBD and
non-CBD aetiologies) to include visuospatial
impairment, speech and language impairment, with
equal weighting of motor and cognitive features.5 8
Several diagnostic criteria have been proposed
for CBS and CBD, but concordance is low between
criteria.8 Even with detailed clinical evaluation and
the widespread availability of structural and func-
tional imaging, misclassiﬁcation rates of CBS and
CBD are high ante mortem. CBD is deﬁned neuro-
pathologically by the abnormal deposition of aggre-
gated 4-repeat tau protein isoforms in neurons and
glial cells, as outlined by Dickson et al.2 In all,
24%–57% patients with CBD (at autopsy) had
been correctly diagnosed in their lifetime.9–11
Conversely, many patients who were diagnosed
with CBS or clinical CBD had another diagnosis by
pathology, most commonly AD and frontotemporal
dementia.4 6
In clinical practice, neuropathology is rarely
available ante mortem. Nonetheless, accurate diag-
nosis of CBD would critically affect enrolment and
power of clinical trials and the applicability of
emerging disease-modifying therapies that target
tau mechanisms of neurodegeneration. The preva-
lence of CBD, and its potential for ‘orphan disease’
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status in regulatory authority approval for new drugs, further
increases the need for accuracy and preferably accuracy early in
the course of the illness. Both clinicians and clinical trial investi-
gators therefore require sensitive and speciﬁc diagnostic criteria
for CBD.
In recently published consensus criteria, Armstrong et al1
sought to improve the accuracy of CBD diagnosis. A signiﬁcant
development in the Armstrong consensus criteria was the use of
pooled neuropathologically-proven cases to determine the clin-
ical phenotype of CBD retrospectively. In doing so, there were
two key innovations. First, they proposed categories of probable
and possible CBD, indicating the degree of certainty of diagno-
sis. Second, they broadened the clinical phenotype associated
with CBD, by including the clinical categories of frontal
behavioural-spatial syndrome (FBS), non-ﬂuent/agrammatic
variant of primary progressive aphasia (NAV) and progressive
supranuclear palsy syndrome (PSPS). Clinical phenotypes and
diagnostic criteria from Armstrong et al are shown in table 1.
These changes acknowledge the spectrum and overlapping phe-
notypes of tau-related neurodegenerative diseases.2–4 Armstrong
et al also acknowledged that clinical evidence of memory
impairment is common, although this was not included in the
criteria.
We tested the new Armstrong et al criteria using patients
from a specialist clinical research centre with detailed longitu-
dinal clinical and neuropathological data. We applied the criteria
to patients with CBD and then applied the criteria to patients
with CBD mimics. This enables an independent assessment of
the Armstrong et al criteria for CBD, and provides new infor-
mation about the performance of the new criteria in patients
with diseases that mimic CBD. We asked two speciﬁc questions:
whether the Armstrong criteria speciﬁcally identify CBD cases
or not, and whether individual clinical features differentiate
CBD from CBD mimics.
METHODS
Patients were recruited from regional specialist clinics for
Disorders of Movement and Cognition and Early-Onset
Dementia at Addenbrooke’s Hospital presenting between 1990
and 2013. Only patients with detailed clinical and pathological
information were included. The original exclusion criteria were
applied (see table 1). Two groups of patients were studied: those
with CBD irrespective of ante mortem clinical diagnosis, and
those with CBD mimics, diagnosed clinically with CBD or CBS
in life but without CBD pathology. Basic demographic data were
similar for the two groups, as given in table 2.
In keeping with UK law on research and retention of human
tissue, all patients with mental capacity were appropriately
counselled and provided written informed consent for inclusion
in research and brain bank donation. Their next of kin or advo-
cate also supported brain donation as part of local procedures.
In the absence of mental capacity, next of kin provided a non-
binding declaration of intent after consultation and counselling
ante mortem, and then provided written informed consent post-
mortem. Appropriate ethical approval was obtained for this
study (Cambridge Research Ethics Committee).
Table 1 Armstrong criteria:1 (A) proposed clinical phenotypes or syndromes; (B) proposed diagnostic criteria for CBD; (C) exclusion criteria for
both clinical research criteria for probable sporadic CBD and possible CBD
(A) Syndrome Feature
Probable CBS Asymmetric presentation of two of: (a) limb rigidity or akinesia, (b) limb dystonia, (c) limb myoclonus
plus two of: (d) orobuccal or limb apraxia, (e) cortical sensory deficit, (f ) alien limb phenomena (more than simple levitation)
Possible CBS May be symmetric: one of: (a) limb rigidity or akinesia, (b) limb dystonia, (c) limb myoclonus plus one of: (d) orobuccal or limb
apraxia, (e) cortical sensory deficit, (f ) alien limb phenomena (more than simple levitation)
Frontal behavioural-spatial syndrome
(FBS)
Two of: (a) executive dysfunction, (b) behavioural or personality changes, (c) visuospatial deficits
NAV of primary progressive aphasia Effortful, agrammatic speech plus at least one of: (a) impaired grammar/sentence comprehension with relatively preserved single
word comprehension or (b) groping, distorted speech production (apraxia of speech)
Progressive supranuclear palsy
syndrome (PSPS)
Three of: (a) axial or symmetric limb rigidity or akinesia, (b) postural instability or falls, (c) urinary incontinence, (d) behavioural
changes, (e) supranuclear vertical gaze palsy or decreased vertical saccade velocity
(B)
Clinical research criteria for
probable sporadic CBD Clinical criteria for possible CBD
Presentation Insidious onset and gradual
progression
Insidious onset and gradual progression
Minimum duration of symptoms, years 1 1
Age at onset, years ≥50 No minimum
Family history (two or more relatives) Exclusion Permitted
Permitted phenotypes (see table 4 for criteria) (1) Probable CBS or (2) FBS or NAV
plus at least one CBS feature (a–f )
(1) Possible CBS or (2) FBS or NAV or (3)
PSPS plus at least one CBS feature (b–f)
Genetic mutation affecting tau (eg, MAPT) Exclusion Permitted
(C)
Exclusion criteria for both clinical research criteria for probable sporadic CBD and
possible CBD
Evidence of Lewy body disease, multiple system atrophy, Alzheimer’s disease or
amyotrophic lateral sclerosis; semantic or logopenic variant primary progressive
aphasia; structural lesion suggestive of focal cause; granulin mutation or reduced
plasma progranulin levels; TDP-43 or fused in sarcoma (FUS) mutations
CBD, corticobasal degeneration; CBS, corticobasal syndrome; NAV, non-fluent/agrammatic variant.
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Clinical records were evaluated for the documented presence
or absence of the clinical features used in the diagnostic criteria
of Armstrong et al. In all patients, the disease was of insidious
onset over more than a year. For each clinical feature, we docu-
mented whether it was present at diagnosis and whether it was
ever present during the patient’s clinical course. These clinical
features are given in table 3. The documented presence or
absence of each feature was summed to generate the denomin-
ator to calculate percentage frequencies in the same way as
Armstrong et al. We applied the Armstrong criteria to each of
the patients in our cohorts of CBD and CBD mimics. Difference
in the frequency of individual clinical features between the
patient groups was examined by χ2 analysis. Descriptive statistics
were performed in Excel with supplemental analysis in ‘R’
software (http://cran.r-project.org/). Neuropathological examin-
ation and diagnosis were undertaken without knowledge of the
clinical features.
RESULTS
CBD
In all, 19 patients were identiﬁed with CBD and comprehensive
and detailed clinical records: 10/19 (52%) of these were given a
diagnosis of CBD at presentation and 13/19 (68%) during their
lifetime. These diagnostic rates are in the upper range of those
previously reported.1 9 12 13 The frequencies of individual clin-
ical features in pathologically conﬁrmed CBD were compared
with published data, as shown in table 3. There was a strong
correlation between the frequency of individual clinical features
in our cohort and that of Armstrong et al: r=0.78 (p=5×10−5)
at presentation and r=0.58 (p=7×10−3) during entire course
of disease. Of note, cognitive impairment was common: present
in 78% patients at diagnosis and 89% during the entire course,
consistent with recently published data.1 5
Patients were classiﬁed ﬁrst according to clinical phenotypes
(syndromes): ‘probable CBS’, ‘possible CBS’, ‘FBS’, ‘NAV’,
‘PSPS’, and thereafter according to whether they met diagnostic
criteria for ‘probable CBD’ or ‘possible CBD’. The diagnostic
criteria for CBD incorporate the clinical phenotype for
example, FBS or NAV. Hence, a patient with an FBS phenotype
and meeting criteria for probable CBD would be classiﬁed as
probable CBD and included in the ‘FBS phenotype’ number in
parentheses. Diagnoses made on this patient group are given in
table 4A. The numbers of patients meeting inclusion criteria for
each of the individual categories are given in parentheses,
Table 2 Demographic data for patients with confirmed CBD
pathology (‘CBD’) and clinical diagnosis of CBD but negative
pathology (‘CBD mimics’); p values for group differences were not
significant for any comparison, by χ2 or t tests as appropriate
Pathology ‘CBD’ ‘CBD mimics’
Number of patients (n) 19 14
M:F ratio 9:10 7:7
Age at presentation (mean±SD) 67 (8) 69 (9)
Duration of disease, diagnosis to death
(year; mean±SD)
4 (3) 5 (3)
MMSE at presentation/30 (mean±SD) 15 (8) 21 (5)
ACE-R total at presentation/100 (mean±SD) 51 (25) 65 (13)
CBD, corticobasal degeneration; MMSE, mini mental state examination.
Table 3 Frequency of individual clinical features in patients with pathological CBD in our patient cohort compared with the data
of Armstrong et al1
At presentation n (%) During entire course n (%)
Clinical feature Published Our data Published Our data
Limb rigidity 65/114 (57) 10/17 (59) 153/180 (85) 13/18 (72)
Bradykinesia/clumsy limb 53/111 (48) 10/17 (59) 126/165 (76) 11/18 (61)
Bradykinesia – 8/16 (50) – 11/17 (65)
Clumsy limb – 10/17 (59) – 10/18 (56)
Postural instability 20/49 (41) 4/16 (25) 73/94 (78) 8/17 (47)
Falls 27/76 (36) 3/14 (21) 83/111 (75) 8/15 (53)
Abnormal gait 30/92 (33) 5/17 (29) 102/140 (73) 13/18 (72)
Axial rigidity 18/67 (27) 4/15 (27) 68/98 (69) 5/16 (31)
Tremor 17/83 (20) 7/15 (47) 50/127 (39) 8/16 (50)
Limb dystonia 18/91 (20) 4/17 (24) 47/123 (38) 6/18 (33)
Myoclonus 14/94 (15) 2/15 (13) 34/128 (28) 5/15 (33)
Cognitive impairment (overall) 59/114 (52) 14/18 (78) 123/175 (70) 17/19 (89)
Objective cognitive impairment – 14/18 (78) – 17/19 (89)
Behavioural changes 52/113 (46) 9/17 (53) 82/150 (55) 14/18 (78)
Limb apraxia 46/102 (45) 11/17 (65) 81/142 (57) 14/18 (78)
Aphasia 40/101 (40) 10/19 (53) 80/155 (52) 11/20 (55)
Depression 21/80 (26) 3/16 (19) 42/82 (51) 4/17 (24)
Cortical sensory loss 20/81 (25) 4/17 (24) 29/107 (27) 5/18 (28)
Alien limb 20/90 (22) 5/17 (29) 24/81 (30) 5/18 (28)
Abnormal eye movement 29/88 (33) 7/16 (44) 90/150 (60) 8/16 (50)
Hyperreflexia 17/57 (30) 6/18 (33) 58/116 (50) 6/18 (33)
Speech changes 18/77 (23) 6/15 (40) 59/112 (53) 7/15 (47)
Abnormal eye movement 29/88 (33) 7/16 (44) 90/150 (60) 8/16 (50)
Data given for the presence/absence of each clinical feature at presentation and during the entire course of diagnosed disease. The denominator used was the number of patients with
documented presence/absence of each clinical feature. The percentage frequencies of individual clinical features in our cohort and that of Armstrong et al1 were strongly correlated:
r=0.78 at presentation and r=0.58 during entire course of disease across all variables (Pearson correlation).
CBD, corticobasal degeneration.
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demonstrating the overlapping and inclusive nature of the pro-
posed categories.
The original diagnoses are given in table 4B. As shown, using
Armstrong et al criteria, 9/19 were diagnosed with probable
CBD at presentation and a further nine patients with possible
CBD. By death, this had increased to 12 probable and one pos-
sible CBD patients. This compares with correct clinical diagnosis
of 10 CBD patients at presentation and 13 by death by previous
criteria. The Armstrong criteria suggest that patients who do not
meet current CBD criteria are more likely to be diagnosed with
one of the other phenotypes associated with predominantly tau
pathology (FBS, NAV and PSPS). In this cohort, PSP, CBD, pro-
gressive non-ﬂuent aphasia or frontotemporal dementia was the
clinical diagnosis in 17/19 patients with CBD at presentation and
all 19 patients by death: only two cases had Alzheimer’s or
Parkinson’s disease. These data suggest that the new diagnostic
criteria do not signiﬁcantly improve the rate of accurate diagnosis
of CBD pathology.
CBD mimics
We next asked whether the new criteria improved the differential
diagnosis of patients in our cohort with non-CBD pathology. We
identiﬁed 14 patients diagnosed with clinical CBD or CBS but
found to have non-CBD pathology at postmortem. Ten had AD
pathology, two had FTLD (with negative tau immunocytochem-
istry) and two had mixed Lewy body and Alzheimer’s pathology
(one with cortical Lewy bodies, the other with Lewy bodies in
the brainstem only; table 5B). We applied the new Armstrong
diagnostic criteria to these CBD mimic patients (table 5A,B).
In all, 9/14 (64%) were still classiﬁed as probable CBD and a
further 5/14 (29%) as possible CBD at presentation; All cases
were classiﬁed with possible or probable CBD at presentation
(table 5A) and throughout the disease course. Only one patient
changed diagnostic category from possible to probable CBD, so
that 10/14 (71%) were classiﬁed as probable CBD and 4/14
(29%) as possible CBD before death. This demonstrates that the
new criteria do not effectively rule out patients with CBS but
non-CBD pathology. Furthermore, all 14 of the non-CBD
patients had neurodegenerative diseases that are not ‘primary’
tauopathies (tau pathology is, of course, a feature of AD, in
combination with β-amyloid). Therefore, the new criteria do
not identify primary tauopathies more accurately.
In order to assess whether individual clinical features were
more commonly associated with CBD pathology, versus CBD
mimics, we performed χ2 analysis on each feature. Several fea-
tures were present more often in CBD mimic cases, including
documented myoclonus (8/11 in CBD mimic cases compared
with 2/15 in CBD pathology group, p=0.006) and visuospatial
deﬁcits (10/13 (77%) in CBD negative cases compared with
8/18 (44%) in CBD, p=0.15). However, no clinical features
were signiﬁcantly more common in the CBD group compared
with CBD mimics.
DISCUSSION
The question for physicians and clinical trial investigators is
simple: for a patient with clinically suspected CBD (or CBS) can
we know whether they have CBD? The recent diagnostic criteria
proposed by Armstrong et al1 are not sufﬁcient to answer this
question. The new criteria continue to misdiagnose CBD
mimics as CBD, and fail to identify about a third of cases with
CBD, even when applied late in the course of the disease.
We applaud the work of Armstrong et al in their aim of
advancing a challenging area of clinical diagnostics and support
the inclusion of a PSP syndrome and a FBS within the spectrum
of CBS. These changes acknowledge the overlapping pheno-
types of tau-related disorders, including PSP and FTLD-tau.
However, our data demonstrate that the Armstrong criteria do
Table 4 (A) Diagnostic classification for patients with
pathologically confirmed CBD using criteria proposed by Armstrong
et al.1 Patients were classified first according to clinical syndromes:
‘probable CBS’, ‘possible CBS’, ‘FBS’, ‘NAV’, ‘PSPS’, and thereafter
according to whether they met diagnostic criteria for ‘probable
CBD’ and/or ‘possible CBD’. The diagnostic criteria for CBD
incorporate the clinical phenotype, for example, FBS or NAV, so a
patient with one of these phenotypes and also meeting criteria for
probable CBD would be classified as probable CBD and included in
the FBS/NAV number in parentheses. (B) Diagnoses given to
patients at presentation and final diagnosis during their lifetime
At presentation During lifetime
(A) Diagnosis Primary diagnosis Primary diagnosis
Probable CBD 9 12
Possible CBD 9 (18 including
‘Probable CBD’)
1 (13 including
‘Probable CBD’)
Probable CBS 3 4
Possible CBS 4 (7) 6 (10)
Frontal behavioural-spatial
(FBS)
0 (12) 2 (13)
FBS–NAV overlap 0 1
Non-fluent/agrammatic
variant (NAV)
0 (11) 3 (12)
PSP phenotype 1 (1) 0 (6)
(B) Diagnosis At presentation During lifetime
CBD 10 13
PNFA 2 2
FTD 4 4
PSP 1 0
Other 2 (1 AD, 1 IPD) 0
AD, Alzheimer’s disease; CBD, corticobasal degeneration; FTD, frontotemporal
dementia; IPD, idiopathic Parkinson’s disease; PNFA, progressive non-fluent aphasia;
PSP, progressive supranuclear palsy; PSPS, progressive supranuclear palsy syndrome.
Table 5 (A) Diagnostic classification for patients with ‘CBD
mimics’, mimicking CBD clinically but with non-CBD pathology,
using criteria proposed by Armstrong et al.1 (B) Postmortem
findings in clinical mimics of CBD
(A) Diagnosis
At
presentation
During
lifetime
Probable CBD 9 10
Possible CBD 5 4
Probable CBS 2 4
Possible CBS 8 (10) 10 (14)
Frontal behavioural-spatial (FBS)
phenotype
0 (7) 0
Non-fluent/agrammatic variant 0 (3) 0
Progressive supranuclear palsy phenotype 0 (1) 0
(B) Postmortem
Alzheimer’s disease 10
Frontotemporal dementia (TDP-43) 2
Mixed Alzheimer’s disease/Lewy body disease 2
CBD, corticobasal degeneration; CBS, corticobasal syndrome.
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not improve upon the longstanding difﬁculty of identifying
patients with CBD sufﬁciently to improve the prospects of clin-
ical trials. A third of patients with CBD do not meet the new
criteria, while the new criteria fail to rule out common CBD
mimics where patients with CBS have underlying non-CBD
pathology.
We acknowledge potential shortcomings of this study, in par-
ticular those of sample size and retrospective analysis. The
patient groups are relatively small compared with the data used
to derive the Armstrong et al criteria. However, our study size is
in the upper range of other published series of CBD and CBS,
including those contributing to the Armstrong criteria, reﬂecting
that CBD is a relatively uncommon disease.1 9 10 11 Our data
draw on detailed clinical phenotyping and pathological study
over many years, and provide an objective evaluation of the new
criteria in this context. A consequence of the retrospective
nature of this study is that some clinical features might have
been less well documented in some patients, and a uniﬁed clin-
ical pro forma to ensure systematic recording of all features
(present or absent) was only adopted in 2005. Omissions are,
we suggest, more likely to reﬂect the absence of a particular
feature in a given case, but this cannot be conﬁrmed in retro-
spect. Prospectively collected data based on these criteria will be
helpful in resolving some of these issues.
The chief difﬁculty of distinguishing CBD from CBD mimics
lies in the very similar CBS phenotypes arising from CBD and
non-CBD pathologies. Surprisingly, none of the individual clin-
ical features are more prevalent with CBD than non-CBD cases
of CBS, suggesting that analyses of clinical features alone are
insufﬁcient for accurate diagnosis. A solution may be to
combine clinical with biomarker data to provide additional
information, including neuroimaging biomarkers or cerebro-
spinal ﬂuid (CSF) biochemistry. This approach was used by
Burrell et al12 who used the positron emission tomography
(PET) ligand PiB to study patients with clinical CBD (ie, CBS)
to investigate differences in clinical phenotype between those
with extensive amyloid burden and those without, albeit
without neuropathology. Rabinovici and colleagues compared
the sensitivity and speciﬁcity of ﬂurodeoxyglucose-PET and
PiB-PET in patients with AD and frontotemporal dementia. In
neuropathologically conﬁrmed cases, the authors found that PiB
was slightly superior with a sensitivity of 89.5% for AD and
speciﬁcity of 83%.13 However, PiB correlates poorly with the
distribution of hypometabolism and clinical syndromes between
different variants of AD.14 CSF biomarkers are also an area of
active investigation in CBD. Borroni et al,15 for example,
reported that CSF tau to Aβ ratio correlated with 99mTc-ECD
single photon emission CT scan results suggestive of a diagnosis
of Alzheimer’s pathology, although also without neuropatho-
logical conﬁrmation of diagnosis. Validating such neuroimaging
or CSF biomarker ﬁndings with neuropathology will be import-
ant in the absence of an accurate ‘gold standard’ by clinical diag-
nostic criteria. Our study lacks such biomarkers. It is possible
that a clinical diagnosis of CBS together with negative biomar-
kers for AD pathology (eg, negative PiB/low CSF tau to Aβ
ratio) would accurately identify cases of CBD, but this requires
conﬁrmation. The development of novel tau ligands for PET
imaging16 17 may also lead to an important role of PET in the
accurate diagnosis of CBD and CBD mimics.
The difﬁculty of reliably detecting CBD pathology continues
to slow the development and application of effective
mechanism-based therapies. Higher accuracy would increase
power to detect a therapeutic effect, compared with trials which
include a substantial proportion of AD or TDP-43-based FTLD.
Better criteria for the diagnosis of CBD and CBS are still
required, which may include imaging biomarkers.
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